Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 101

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 6
Chunk 101
---
ugene Limited (ASX: IMU),
which he founded in October 2012 and Chimeric Therapeutics Limited (ASX:CHM), which he founded in 2019. In addition, Mr. Hopper was also
previously Chairman at Viralytics Limited (ASX: VLA) until it was acquired by Merck in 2018. He was previously Executive Chairman of Arovella
Therapeutics (ASX:PTX) between May 2019 and June 2022, as well as a director of Prescient Therapeutics Limited (ASX: PTX) from May 2014
to January 2020. Mr. Hopper brings 20 years’ experience in the management and funding of biotechnology and healthcare companies
in Australia and the United States.

Dimitris Voliotis.
Dimitris Voliotis has been the Chief Medical Officer of Radiopharm since August 2024. Dr. Voliotis has 20 years of pharma and biotechnology
expertise across the United States and Europe, with an emphasis on the radiopharmaceutical sector, and 12 years of experience in academic
preclinical and clinical research as a Senior Consultant in Oncology and Head, Laboratory for Diagnostic Hematology and lmmunohematology
at the University of Cologne Medical School. Dr. Voliotis has designed and executed multiple registrational trials in numerous oncology
indications, multiple INDs, preclinical through to first in human trials. In particular, Dr. Voliotis has overseen numerous regulatory
submissions that have resulted in approvals for four drugs in eight different oncology indications. Prior to his appointment as Chief
Medical Officer of Radiopharm, Dr. Voliotis was Senior Vice President, Head of Clinical Development of radiopharmaceutical business Convergent
Therapeutics from July 2023 to July 2024, Senior Vice President, Head of clinical development at Zentalis Pharmaceuticals, Inc. (Nasdaq:
ZNTL) from February 2020 to September 2022, a consultant in oncology drug development with Magnesia Partners Consulting LLC, advising
across clinical development and regulatory strategy since September 2022. Prior to that, Dr. Voliotis had spent a combined almost 19
years in a range of development roles with major German multinational pharma company Bayer AG, from November 2001 to September 2014,
and with Japanese company Eisai Inc,